Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06477133 · ClinicalTrials.gov registry record · Phase 4
Magnesium Sulfate as an Adjunctive Analgesic in Prostate Surgery
A Phase 4 study of Prostatectomy, sponsored by NYU Langone Health.
- Active
- Registry status
- Phase 4
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT06477133: Active Phase 4 study of Prostatectomy, sponsored by NYU Langone Health.
NCT06477133 is a Phase 4 study of Prostatectomy that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 68 participants, below the 114-participant average among 4 other Prostatectomy trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06477133, a Phase 4 study of Prostatectomy, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to determine if receiving magnesium sulfate as an adjunctive analgesic for prostate surgery is effective in reducing pain. Subjects will be randomized to receive magnesium or not receive it, as part of a standardized general anesthetic for prostate surgery. The primary objective is to demonstrate improved pain scores in patients receiving magnesium sulfate as an adjunctive analgesic during surgery. Secondary objectives include demonstrating reduced requirements for other opioids, reduced postoperative shivering, improved discharge home and adequate neuromuscular blockade reversal, measured by quantitative train of four monitoring.
Primary Outcome
Patients will be asked to assess their pain based on a 10-point scale, where 0=no pain and 10=worst imaginable pain.
Conditions Studied
Interventions
- DRUG Magnesium sulfate
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
What the registry record for NCT06477133 still lists
NCT06477133 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 114-participant average among 4 other Prostatectomy trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Prostatectomy appearing as the primary indexed condition, and to 1 intervention - of which Magnesium sulfate is the first listed.
NCT06477133 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06477133 about?
NCT06477133 is a clinical study titled "Magnesium Sulfate as an Adjunctive Analgesic in Prostate Surgery". The purpose of this clinical trial is to determine if receiving magnesium sulfate as an adjunctive analgesic for prostate surgery is effective in reducing pain. Subjects will be randomized to receive magnesium or not receive it, as part of a standardized general anesthetic for prostate surgery. The ...
What is the current status of trial NCT06477133?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2024-06-04. Estimated completion is 2026-06.
What conditions does trial NCT06477133 study?
This clinical trial studies the following conditions: Prostatectomy.
What interventions are being tested in trial NCT06477133?
The interventions under investigation include: Magnesium sulfate (DRUG).
Who is sponsoring clinical trial NCT06477133?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06477133 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatectomy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TAP-patients With Robotic Assisted Lap Prostatectomy
COMPLETED · Phase 4
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI